Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $106.00.

A number of equities analysts have commented on the stock. Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Morgan Stanley increased their target price on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Wedbush restated an “outperform” rating and issued a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Finally, HC Wainwright lifted their price target on shares of Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a report on Thursday.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $77.44 on Friday. The company has a market cap of $2.96 billion, a PE ratio of -11.77 and a beta of 1.00. The business’s 50 day moving average is $73.59 and its two-hundred day moving average is $69.79. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine has a 52 week low of $40.00 and a 52 week high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. On average, analysts predict that Disc Medicine will post -6.61 EPS for the current year.

Insider Buying and Selling

In other news, COO Jonathan Yen-Wen Yu sold 9,700 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $72.66, for a total transaction of $704,802.00. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $3,947,181.84. This represents a 15.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rahul Khara sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the sale, the insider owned 52,324 shares in the company, valued at $4,185,920. The trade was a 8.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 110,712 shares of company stock worth $7,997,536 over the last quarter. 3.76% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming bought a new position in Disc Medicine during the 2nd quarter worth $25,000. ANTIPODES PARTNERS Ltd bought a new stake in Disc Medicine in the fourth quarter valued at $33,000. KBC Group NV acquired a new position in shares of Disc Medicine during the fourth quarter valued at $80,000. Persistent Asset Partners Ltd acquired a new position in shares of Disc Medicine during the fourth quarter valued at $141,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Disc Medicine by 36.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after acquiring an additional 490 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine News Summary

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and raised its price target to $120. The target is well above the stock’s recent trading level, signaling substantial expected upside if Disc Medicine’s clinical and commercial plans progress. HC Wainwright analyst estimates
• Positive Sentiment: HC Wainwright modestly improved its EPS forecasts for fiscal 2026, the fourth quarter of 2026 and fiscal 2028. Although the company is expected to remain unprofitable in those periods, the revisions indicate slightly better projected results. The firm expects earnings to turn positive in 2029.
• Neutral Sentiment: The analyst’s estimates were mixed overall: forecasts improved for some periods but were lowered for fiscal 2027, 2029 and 2030. The changes were small and did not alter the firm’s bullish rating or $120 target, suggesting limited immediate impact on valuation expectations.
• Negative Sentiment: Rosen Law Firm said it is investigating potential securities claims on behalf of Disc Medicine shareholders over allegations that the company may have issued materially misleading business information. The announcement does not establish wrongdoing or confirm that a lawsuit will be filed, but it could increase legal costs and investor uncertainty. Rosen Law Firm investigation notice
• Negative Sentiment: Insider Rahul Khara sold 5,000 shares for approximately $400,000, reducing his ownership by 8.72%. He still holds 52,324 shares, so the transaction does not necessarily indicate a change in company fundamentals, but repeated insider selling can pressure investor sentiment. SEC insider filing

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.